… predictors of response. Seventy patients with relapsed non–small cell lung carcinoma were
… After the drug became available commercially, 28 more patients were treated with gefitinib. …

… of gefitinib responders, by analyzing the response and … lesions by gefitinib in responders
and the results of gefitinib … with, gefitinib) following temporary cessation of gefitinib upon …

… of response and toxicity in persons with lung cancer. Many of the principles of management
relevant to gefitinib are … on the use of gefitinib in patients with non–small-cell lung cancer. …

… -tumor effects and improved symptoms and quality-of-life of a subset of patients with advanced
non-small cell lung cancer … to predict the response of NSCLC patients to gefitinib, we used …

… To evaluate the efficacy of re-challenge of gefitinib to the initial gefitinib responders, we …
to initial gefitinib and re-administrated gefitinib following chemotherapy. The response rate and …

… (Iressa) in a patient with advanced non-small-cell lung cancer and poor performance status.
Lung … EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. …

… lung disease (ILD) has been reported in patients with non-small cell lung cancer (NSCLC)
treated with gefitinib in … advanced NSCLC who received gefitinib monotherapy. Univariate and …

… The median survival time (MST) of all patients receiving gefitinib treatment was 10 … 39
gefitinib responders and 6 months in the 92 non-responders. Among the 39 gefitinib responders, …

… difference was seen in the response rate to gefitinib 250 or 500 mg/day (12 versus 9%).
Median survival was 7 months with gefitinib 250 mg/day and 6 months with gefitinib 500 mg/day …

… -cell lung cancer who had a response to gefitinib, those who did not have a response, and
those who had not been exposed to gefitinib… mutant proteins were expressed in cultured cells. …